For laboratory research use only — not for human consumption
For laboratory research use only — not for human consumption
Metabolic & receptor-signalling research
Triple-agonist peptide (GLP-1 / GIP / glucagon) · CAS 2381089-83-2 · C221H342N46O68
Retatrutide is a synthetic triple-agonist peptide investigated in laboratory research into metabolic and receptor-signalling pathways. It is studied for its simultaneous activity across the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems — the reason it appears frequently in comparative metabolic-research literature alongside single-agonist (GLP-1) and dual-agonist (GLP-1/GIP) reference peptides.
Structurally it is a 39-residue peptide (molecular formula C221H342N46O68, CAS 2381089-83-2) carrying a fatty-acid moiety that extends its half-life in solution — a feature that makes it a useful comparator in peptide-stability and receptor-pharmacology research. Its triple-receptor profile distinguishes it from the tirzepatide (dual-agonist) and semaglutide (single-agonist) reagents it is most often benchmarked against.
Argon supplies retatrutide to Australian laboratories and qualified researchers as a lyophilised powder, in 10 mg and 20 mg vial sizes, each independently characterised by HPLC and mass spectrometry with a Certificate of Analysis published per batch. It is discussed strictly in an in-vitro research context and is not for human or veterinary use.
As with any research reagent, characterisation data rather than anecdote is the basis for evaluating a batch: the published COA reports purity (this batch, 99.66% by HPLC), identity by mass spectrometry, and appearance. Reported observations described in the research literature — including any adverse or off-target findings — belong to the primary studies that generated them and are not use, safety, or dosing claims made by Argon.
Supplied as a lyophilised powder in 10 mg and 20 mg vials. Reconstitute with bacteriostatic water (or sterile water) for laboratory preparation — the resulting concentration is the vial mass divided by the water volume, so a 10 mg vial in 2 mL gives 5 mg/mL. Add solvent gently down the side of the vial, swirl rather than shake, and store the reconstituted solution cold and protected from light; store the unreconstituted powder at -20°C. Our retatrutide reconstitution calculator works out the concentration and the volume that corresponds to any target aliquot mass.
Retatrutide is supplied strictly for in-vitro laboratory research use only. Not for human or veterinary use. This page describes areas of scientific study and does not make any therapeutic, dosing, or human-use claim.
